{"protocolSection":{"identificationModule":{"nctId":"NCT03735121","orgStudyIdInfo":{"id":"BP40657"},"secondaryIdInfos":[{"id":"2018-002328-18","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","officialTitle":"A Randomized, Multicenter, Phase Ib/III Study to Investigate the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Subcutaneous Compared With Atezolizumab Intravenous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2025-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-12-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-04-26","type":"ACTUAL"},"completionDateStruct":{"date":"2024-11-11","type":"ACTUAL"},"studyFirstSubmitDate":"2018-11-07","studyFirstSubmitQcDate":"2018-11-07","studyFirstPostDateStruct":{"date":"2018-11-08","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-04-25","resultsFirstSubmitQcDate":"2023-06-12","resultsFirstPostDateStruct":{"date":"2023-06-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-11-20","lastUpdatePostDateStruct":{"date":"2025-12-05","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study will evaluate the pharmacokinetics, safety, and efficacy of atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV) in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) who have not been exposed to cancer immunotherapy (CIT) and for whom prior platinum-based therapy has failed. The study is comprised of two parts, as follows: A dose-finding part (Part 1, Phase Ib) will aim to identify the dose of atezolizumab SC to be tested in Part 2. A dose-confirmation part (Part 2, Phase III, randomized) will aim to confirm that the dose moved forward from Part 1 yields drug exposure that is comparable to that of atezolizumab IV."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","interventionModelDescription":"Intervention study model can be sequential or in parallel.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":438,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Atezolizumab (Part 2)","type":"EXPERIMENTAL","description":"Atezolizumab","interventionNames":["Drug: Atezolizumab"]},{"label":"Cohort 1: Atezolizumab+rHuPH20 (Part 1)","type":"EXPERIMENTAL","description":"Atezolizumab+recombinant human hyaluronidase (rHuPH20), followed by Atezolizumab","interventionNames":["Drug: Atezolizumab","Drug: rHuPH20"]},{"label":"Cohort 2: Atezolizumab+rHuPH20 (Part 1)","type":"EXPERIMENTAL","description":"Atezolizumab+rHuPH20, followed by Atezolizumab","interventionNames":["Drug: Atezolizumab","Drug: rHuPH20"]},{"label":"Cohort 3: Atezolizumab+rHuPH20(Part 1)","type":"EXPERIMENTAL","description":"Atezolizumab+rHuPH20, followed by Atezolizumab","interventionNames":["Drug: Atezolizumab","Drug: rHuPH20"]},{"label":"Atezolizumab + rHuPH20 (Part 2)","type":"EXPERIMENTAL","description":"Atezolizumab + rHuPH20","interventionNames":["Drug: Atezolizumab","Drug: rHuPH20"]}],"interventions":[{"type":"DRUG","name":"Atezolizumab","description":"Atezolizumab will be administered as per the schedule specified in arm or cohort.","armGroupLabels":["Atezolizumab (Part 2)","Atezolizumab + rHuPH20 (Part 2)","Cohort 1: Atezolizumab+rHuPH20 (Part 1)","Cohort 2: Atezolizumab+rHuPH20 (Part 1)","Cohort 3: Atezolizumab+rHuPH20(Part 1)"],"otherNames":["Tecentriq"]},{"type":"DRUG","name":"rHuPH20","description":"rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.","armGroupLabels":["Atezolizumab + rHuPH20 (Part 2)","Cohort 1: Atezolizumab+rHuPH20 (Part 1)","Cohort 2: Atezolizumab+rHuPH20 (Part 1)","Cohort 3: Atezolizumab+rHuPH20(Part 1)"],"otherNames":["ENHANZE"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1","timeFrame":"Pre-dose on Day 1 of Cycle 2 (Cycle length=21 days for cohorts 1 and 3 and 14 days for cohort 2)"},{"measure":"Part 2: Observed Serum Ctrough of Atezolizumab at Cycle 1","timeFrame":"Predose on Day 1 of Cycle 2 (Cycle length =21 days)"},{"measure":"Part 2: Area Under the Concentration-Time Curve From Time Zero to 21 Days (AUC 0-21 d) at Cycle 1","timeFrame":"From start of dosing up to Day 21 in Cycle 1 (Cycle length = 21 days)"}],"secondaryOutcomes":[{"measure":"Part 1: Maximum Observed Serum Concentration (Cmax) of Atezolizumab","timeFrame":"Predose and post dose on Day 1 of Cycle 1 and post dose on Days 3 and 8 of Cycle 1 (Cycle length = 21 days for cohorts 1 and 3 and 14 days for cohort 2)"},{"measure":"Part 1: Time to Maximum Serum Concentration (Tmax) of Atezolizumab","timeFrame":"Predose and post dose on Day 1 of Cycle 1 and post dose on Days 3 and 8 of Cycle 1 (Cycle length = 21 days for cohorts 1 and 3 and 14 days for cohort 2)"},{"measure":"Part 1: Area Under the Concentration-time Curve (AUClast) of Atezolizumab","timeFrame":"Predose and up to 21 days post dose in Cycle 1 for cohorts 1 and 3 and from predose up to 14 days post last dose in Cycle 1 for cohort 2 (Cycle length= 21 days for cohorts 1 and 3 and 14 days for cohort 2)"},{"measure":"Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration","description":"Cycle length =21 days for cohorts 1 and 3 and 14 days for cohort 2. Day=D; Cycle=C.","timeFrame":"Cohort 1: Predose: D1 & postdose: D1, 3, 8 of C1; Cohort 2: Pre & postdose: D1 of C1, 3 & postdose: D3, 8 of C1, Predose: D1 of C2; Cohort 3: Pre & postdose: D1 of C1, 2 & postdose: D3, 8 of C1, D2, 4 & 9 of C2 & pre dose: D1 of C3"},{"measure":"Part 1: Percentage of Participants With Adverse Events (AEs)","description":"An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 5.0 (NCI-CTCAE, v5.0). Percentages have been rounded to one decimal place.","timeFrame":"From initiation of study treatment up to approximately 69 months"},{"measure":"Part 2: Percentage of Participants With AEs","description":"An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, V5.0. Percentages have been rounded to one decimal place.","timeFrame":"From initiation of study treatment up to approximately 44.7 months"},{"measure":"Part 2: Model Predicted Ctrough of Atezolizumab at Cycle 1","timeFrame":"Cycle 1 (Cycle length=21 days)"},{"measure":"Part 2: Model Predicted Ctrough at Steady State (Ctrough,ss) of Atezolizumab","description":"1 cycle=21 days Abbreviations used-Cycle=C; Day =D; Atezolizumab=atezo.","timeFrame":"Atezo SC: Pre&postdose C1D1, postdose C1 Days 2,4,8, Pre&postdose C2,D1 and Predose on D1 of C3,4,8,12 and 16 ; Atezo IV: Pre&postdose on C1D1, postdose C1 Days 2,4,8; Pre&postdose C2D1, Predose on D1 of C3,4,8,12, and 16 (up to approximately 16 months)"},{"measure":"Part 2: Model Predicted AUC at Steady State (AUCss) of Atezolizumab","description":"1 cycle=21 days Abbreviations used-Cycle=C; Day =D; Atezolizumab=atezo","timeFrame":"Atezo SC: Pre&postdose C1D1, postdose C1 Days 2,4,8, Pre&postdose C2,D1 and Predose on D1 of C3,4,8,12 and 16 ; Atezo IV: Pre&postdose on C1D1, postdose C1 Days 2,4,8; Pre&postdose C2D1, Predose on D1 of C3,4,8,12, and 16 (up to approximately 16 months)"},{"measure":"Part 2: Objective Response Rate (ORR)","description":"ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1). CR was defined as the disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \\< 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of all target lesions, taking as reference the baseline SOD in the absence of CR. Percentage of participants who achieved confirmed objective response (CR or PR) have been reported. Percentages have been rounded to one decimal place.","timeFrame":"Up to approximately 25 months"},{"measure":"Part 2: Progression-free Survival (PFS)","description":"PFS was defined as the time from study start to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first). PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm. PFS was analyzed using the Kaplan-Meier method.","timeFrame":"Up to approximately 25 months"},{"measure":"Part 2: Overall Survival (OS)","description":"OS was defined as the time from the date of study randomization to the date of death from any cause.","timeFrame":"Up to approximately 44.7 months"},{"measure":"Part 2: Duration of Response (DOR)","description":"DOR was defined as the time from first occurrence of a documented confirmed objective response (CR or PR) to PD as determined by the investigator according to RECIST v1.1. or death from any cause, whichever occurs first. CR was defined as the disappearance of all target lesions and any pathological lymph nodes must have a reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SODs must also demonstrate an absolute increase of ≥ 5 mm.","timeFrame":"Up to approximately 25 months"},{"measure":"Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score","description":"EORTC IL57 questionnaire has 10 items and covers 3 scales: physical functioning (PF), role functioning (RF) \\& global health status/quality of life (GHS/QoL) \\& 1 item from EORTC IL. PF scale has 5 items evaluating the extent to which participants have trouble doing strenuous activities; taking long walks \\& short walks; need to stay in bed or a chair; need help with eating, dressing, bathing/using toilet. RF scale has 2 items evaluating extent to which participants are limited in doing work \\& pursuing leisure activities in previous week. GHS/QoL scale has 2 items evaluating participants' overall health \\& QoL in previous week. Questions are answered on a 4-point Likert scale (where 1=\"Not at all\" to 4=\"Very much\") for physical and role functioning \\& a 7-point scale (where 1=\"Very poor\" to 7=\"Excellent\") for GHS/QoL. For each scale, mean of the items are linearly transformed to obtain scores from 0-100, where 100 = best possible score. Higher score indicates better outcome.","timeFrame":"Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 (Cycle length = 21 days), and Treatment Discontinuation Visit (up to approximately 44 months)"},{"measure":"Part 2: Change From Baseline in EORTC IL57 Role Functioning Score","description":"EORTC IL57 questionnaire has 10 items and covers 3 scales: PF, RF \\& GHS/QoL \\& 1 item from EORTC IL. PF scale has 5 items evaluating the extent to which participants have trouble doing strenuous activities; taking long walks \\& short walks; need to stay in bed or a chair; need help with eating, dressing, bathing/using toilet. RF scale has 2 items evaluating extent to which participants are limited in doing work \\& pursuing leisure activities in previous week. GHS/QoL scale has 2 items evaluating participants' overall health \\& QoL in previous week. Questions are answered on a 4-point Likert scale (where 1=\"Not at all\" to 4=\"Very much\") for physical and role functioning \\& a 7-point scale (where 1=\"Very poor\" to 7=\"Excellent\") for GHS/QoL. For each scale, mean of the items are linearly transformed to obtain scores from 0-100, where 100 = best possible score. Higher score indicates better outcome.","timeFrame":"Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 (Cycle length = 21 days), and Treatment Discontinuation Visit (up to approximately 44 months)"},{"measure":"Part 2: Change From Baseline in EORTC IL57 Global Health Status Score","description":"EORTC IL57 questionnaire has 10 items and covers 3 scales: PF, RF \\& GHS/QoL \\& 1 item from EORTC IL. PF scale has 5 items evaluating the extent to which participants have trouble doing strenuous activities; taking long walks \\& short walks; need to stay in bed or a chair; need help with eating, dressing, bathing/using toilet. RF scale has 2 items evaluating extent to which participants are limited in doing work \\& pursuing leisure activities in previous week. GHS/QoL scale has 2 items evaluating participants' overall health \\& QoL in previous week. Questions are answered on a 4-point Likert scale (where 1=\"Not at all\" to 4=\"Very much\") for physical and role functioning \\& a 7-point scale (where 1=\"Very poor\" to 7=\"Excellent\") for GHS/QoL. For each scale, mean of the items are linearly transformed to obtain scores from 0-100, where 100 = best possible score. Higher score indicates better outcome.","timeFrame":"Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 (Cycle length = 21 days), and Treatment Discontinuation Visit (up to approximately 44 months)"},{"measure":"Part 2: Overall Satisfaction With Treatment Over Time, Assessed by the Modified Satisfaction With Therapy (SWT) Scale of the Cancer Therapy Satisfaction Questionnaire (CTSQ)","description":"Modified SWT scale of the CTSQ consisted of seven items that measured seven domains related to satisfaction with cancer therapy. These include worthwhile, difficulty, benefits, feelings about side effects, form of therapy, overall satisfaction, and if participants would choose the therapy taking everything into consideration. Each domain is rated on a 5-point scale, with 1 representing the worst response and 5 representing the best response, except in the case of one reverse-scored item. Mean of the items were linearly transformed to obtain scores from 0-100, where 100 was the best possible score. Higher scores indicate higher satisfaction. Here, data for 'overall satisfaction' domain has been presented.","timeFrame":"Day 1 Cycle 3 or Treatment Discontinuation Visit (if treatment discontinued at any visit before Cycle 3) (Cycle length = 21 days)"},{"measure":"Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57","description":"The overall patient-reported AE burden was assessed using a single item from the EORTC IL57 questionnaire i.e \"To what extent have you been troubled with side-effects from your treatment?\" The questions were answered on a 4-point Likert scale, where 1=\"Not at all\" to 4=\"Very much\". Higher scores indicated greater AE burden. Percentages have been rounded to one decimal place.","timeFrame":"Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, and 64 (Cycle length = 21 days)"},{"measure":"Part 2: Percentage of Participants With Ant-Drug Antibodies (ADAs) to Atezolizumab After SC or IV Administration","description":"The percentage of ADA-positive participants after atezolizumab administration was reported. Participants who received atezolizumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following atezolizumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Percentages have been rounded to one decimal place.","timeFrame":"From Cycle 1 Day 1 (Cycle length = 21 days) up to treatment discontinuation visit (Up to approximately 20 months)"},{"measure":"Part 2: Percentage of Participants With ADAs to rHuPH20 After SC Administration","description":"The percentage of ADA-positive participants after atezolizumab SC formulated with rHuPH20 administration was reported. Participants who received atezolizumab SC formulated with rHuPH20 were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following rHuPH20 exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 t.u. greater than the titer of the baseline sample (treatment-enhanced ADA response). Percentages have been rounded to one decimal place.","timeFrame":"From Cycle 1 Day 1 (Cycle length = 21 days) up to treatment discontinuation visit (Up to approximately 20 months)"},{"measure":"Part 2: Percentage of Health Care Professionals (HCPs) by Their Response to Question 2 of HCP SC Versus IV Perspective Questionnaire","description":"The HCP SC versus IV Perspective Questionnaire consisted of five items evaluating the number of atezolizumab SC and IV administrations done, convenience, potential time savings, and overall satisfaction with atezolizumab SC and atezolizumab IV, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as an IV infusion and as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 2 is being reported here: Question 2: Which formulation of atezolizumab (SC or IV) do you think is more convenient for you? Responses to this question are reported in the data table. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'first participant in \\[FPI\\]' date to 'last participant last visit \\[LPLV\\]' for Part 2).","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 48 months)"},{"measure":"Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Versus IV Perspective Questionnaire","description":"The HCP SC versus IV Perspective Questionnaire consisted of five items evaluating the number of atezolizumab SC and IV administrations done, convenience, potential time savings, and overall satisfaction with atezolizumab SC and atezolizumab IV, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as an IV infusion and as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 3 is being reported here: Question 3: If used in routine practice, do you think administering atezolizumab SC could save staff time compared to atezolizumab IV? The responses to this question could be Yes; No; Unsure. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2).","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 48 months)"},{"measure":"Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Versus IV Perspective Questionnaire","description":"The HCP SC versus IV Perspective Questionnaire consisted of five items evaluating the number of atezolizumab SC and IV administrations done, convenience, potential time savings, and overall satisfaction with atezolizumab SC and atezolizumab IV, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as an IV infusion and as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 4 is being reported here: Question 4: Overall, were you more satisfied with atezolizumab SC or atezolizumab IV? The responses included: More satisfied with atezolizumab SC; Equally satisfied with both formulations; More satisfied with atezolizumab IV. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2).","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 48 months)"},{"measure":"Part 2: Percentage of HCPs by Their Response to Question 2 of the HCP SC Perspective Questionnaire","description":"The HCP SC Perspective Questionnaire consisted of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 2 is being reported here: Question 2: Do you think atezolizumab SC is convenient? The responses to this question could be: Yes; No; and Unsure. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2). Percentages have been rounded to one decimal place.","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months)"},{"measure":"Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Perspective Questionnaire","description":"The HCP SC Perspective Questionnaire consisted of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 3 is being reported here: Question 3: Overall, how easy did you find atezolizumab SC administration? The responses to this question could be: Very easy; Fairly easy; Not at all easy. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2). Percentages have been rounded to one decimal place.","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months)"},{"measure":"Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Perspective Questionnaire","description":"The HCP SC Perspective Questionnaire consisted of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 4 is being reported here: Question 4: Overall, how satisfied were you with atezolizumab SC? The responses to this question could be: Very satisfied; Satisfied; Dissatisfied; Very dissatisfied. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2). Percentages have been rounded to one decimal place.","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically documented locally advanced or metastatic NSCLC\n* Prior platinum-containing regimen or disease recurrence ≤ 6 months since prior platinum-based adjuvant/neoadjuvant regimen.\n* Measurable disease as defined by RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Life expectancy ≥12 weeks\n* Adequate hematologic and end-organ function\n\nAdditional Inclusion Criteria (Part 2 Only) • Availability of tissue and known epidermal growth factor receptor (EGFR) status\n\nExclusion Criteria:\n\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Uncontrolled or symptomatic hypercalcemia\n* Pregnancy or breastfeeding\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis\n* Severe infection ≤ 4 weeks\n* Treatment with therapeutic oral or IV antibiotics ≤ 2 weeks prior to study treatment\n* Significant cardiovascular disease\n* Prior allogeneic stem cell or solid organ transplantation\n* Treatment with a live, attenuated vaccine ≤ 4 weeks\n* Treatment with systemic immunostimulatory agents ≤ 4 weeks or 5 half-lives of the drug\n* Treatment with systemic immunosuppressive medication ≤ 2 weeks\n\nAdditional Exclusion Criteria (Part 2 Only)\n\n• Tested tumor programmed death-ligand-1 (PD-L1) expression status with an intention to treat the patient if positive","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Fundación CENIT para la Investigación en Neurociencias","city":"Buenos Aires","zip":"C1125ABD","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Centro Oncologico Riojano Integral (CORI)","city":"La Rioja","zip":"F5300COE","country":"Argentina","geoPoint":{"lat":-29.41328,"lon":-66.85637}},{"facility":"Consultorio Dr. Miguel Angel Escudero","city":"Salta","zip":"4400","country":"Argentina","geoPoint":{"lat":-24.80645,"lon":-65.41999}},{"facility":"Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda","city":"Ijuí","state":"Rio Grande do Sul","zip":"98700-000","country":"Brazil","geoPoint":{"lat":-28.38778,"lon":-53.91472}},{"facility":"Hospital Nossa Senhora da Conceicao","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"91350-200","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Instituto do Cancer do Estado de Sao Paulo - ICESP","city":"São Paulo","state":"São Paulo","zip":"01246-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"INCA 1- Instituto Nacional de Câncer X","city":"Rio de Janeiro","zip":"20231-050","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"Bradford Hill Centro de Investigaciones Clinicas","city":"Recoleta","zip":"8420383","country":"Chile","geoPoint":{"lat":-33.41667,"lon":-70.65}},{"facility":"James Lind Centro de Investigación Del Cáncer","city":"Temuco","zip":"4800827","country":"Chile","geoPoint":{"lat":-38.73628,"lon":-72.59738}},{"facility":"Oncocentro Apys","city":"Viña del Mar","zip":"2520598","country":"Chile","geoPoint":{"lat":-33.02457,"lon":-71.55183}},{"facility":"Jilin Cancer Hospital","city":"Changchun","zip":"132013","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"West China Hospital - Sichuan University","city":"Chengdu","zip":"610047","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Sir Run Run Shaw Hospital Zhejiang University","city":"Hangzhou","zip":"310016","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Jinan Central Hospital","city":"Jinan","zip":"250013","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Henan Cancer Hospital","city":"Zhengzhou","zip":"450008","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"Clinica CIMCA","city":"San José","zip":"10103","country":"Costa Rica","geoPoint":{"lat":9.93388,"lon":-84.08489}},{"facility":"ICIMED Instituto de Investigación en Ciencias Médicas","city":"San José","zip":"10108","country":"Costa Rica","geoPoint":{"lat":9.93388,"lon":-84.08489}},{"facility":"APHM","city":"Marseille","zip":"13385","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Ico Rene Gauducheau","city":"Saint-Herblain","zip":"44805","country":"France","geoPoint":{"lat":47.21154,"lon":-1.651}},{"facility":"General Hospital \"G.Papanikolaou\"","city":"Asvestochóri","zip":"570 10","country":"Greece","geoPoint":{"lat":40.64125,"lon":23.02528}},{"facility":"Sotiria Hospital","city":"Athens","zip":"104 31","country":"Greece","geoPoint":{"lat":37.98376,"lon":23.72784}},{"facility":"INTEGRA Cancer Institute","city":"Guatemala City","zip":"01010","country":"Guatemala","geoPoint":{"lat":14.64072,"lon":-90.51327}},{"facility":"Oncomedica","city":"Guatemala City","zip":"01010","country":"Guatemala","geoPoint":{"lat":14.64072,"lon":-90.51327}},{"facility":"Grupo Angeles","city":"Guatemala City","zip":"01015","country":"Guatemala","geoPoint":{"lat":14.64072,"lon":-90.51327}},{"facility":"Hospital El Pilar","city":"Guatemala City","zip":"01015","country":"Guatemala","geoPoint":{"lat":14.64072,"lon":-90.51327}},{"facility":"Matrai Gyogyintezet","city":"Mátraháza","zip":"3233","country":"Hungary","geoPoint":{"lat":47.87124,"lon":19.97981}},{"facility":"Református Pulmonológiai Centrum","city":"Törökbálint","zip":"2045","country":"Hungary","geoPoint":{"lat":47.42931,"lon":18.91356}},{"facility":"Asst Papa Giovanni XXIII","city":"Bergamo","state":"Lombardy","zip":"24128","country":"Italy","geoPoint":{"lat":45.69601,"lon":9.66721}},{"facility":"IRCCS Istituto Clinico Humanitas","city":"Rozzano","state":"Lombardy","zip":"20089","country":"Italy","geoPoint":{"lat":45.38193,"lon":9.1559}},{"facility":"Riga East Clinical University Hospital Latvian Oncology Centre","city":"Riga","zip":"LV-1079","country":"Latvia","geoPoint":{"lat":56.946,"lon":24.10589}},{"facility":"Health Pharma Professional Research","city":"Mexico City","state":"Mexico CITY (federal District)","zip":"03100","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Cuidados oncologicos","city":"Querétaro City","state":"Querétaro","zip":"76000","country":"Mexico","geoPoint":{"lat":20.58806,"lon":-100.38806}},{"facility":"Auckland City Hospital, Cancer and Blood Research","city":"Auckland","zip":"1023","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Christchurch Clinical Studies Trust Ltd","city":"Christchurch","country":"New Zealand","geoPoint":{"lat":-43.53333,"lon":172.63333}},{"facility":"Waikato Hospital - Cancer and Blood Research Trials Unit","city":"Hamilton","zip":"3204","country":"New Zealand","geoPoint":{"lat":-37.78333,"lon":175.28333}},{"facility":"Tauranga Hospital, Clinical Trials Unit","city":"Tauranga","zip":"3112","country":"New Zealand","geoPoint":{"lat":-37.68611,"lon":176.16667}},{"facility":"Centro Medico Monte Carmelo","city":"Arequipa","zip":"04001","country":"Peru","geoPoint":{"lat":-16.39899,"lon":-71.53747}},{"facility":"Clínica San Gabriel","city":"Lima","zip":"15088","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Oncosalud Sac","city":"Lima","zip":"41","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Clinica Internacional, Sede San Borja","city":"Lima","zip":"Lima 41","country":"Peru","geoPoint":{"lat":-12.04318,"lon":-77.02824}},{"facility":"Regionalny Szpital Specjalistyczny im. W. Bieganskiego","city":"Grudzi?dz","zip":"86-300","country":"Poland"},{"facility":"Centrum Terapii Wspolczesnej","city":"Lodz","zip":"93-319","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy","city":"Otwock","zip":"05-400","country":"Poland","geoPoint":{"lat":52.10577,"lon":21.26129}},{"facility":"Narodowy Instytut Onkologii im. M. Sklodowskiej-Curie","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Chelyabinsk Regional Clinical Oncology Dispensary","city":"Chelyabinsk","state":"Moscow Oblast","zip":"454087","country":"Russia"},{"facility":"FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF","city":"Moscow","state":"Moscow Oblast","zip":"115478","country":"Russia"},{"facility":"MEDSI Clinical Hospital on Pyatnitsky Highway","city":"Moscow","state":"Moscow Oblast","zip":"143422","country":"Russia"},{"facility":"Filial #1 Regional Oncology Dispensary of Nizhniy Novgorod","city":"Nizhny Novgorod","state":"Niznij Novgorod","zip":"603081","country":"Russia","geoPoint":{"lat":56.32867,"lon":44.00205}},{"facility":"Mordovia State University","city":"Saransk","state":"Respublika Mordoviya","zip":"430032","country":"Russia","geoPoint":{"lat":54.18485,"lon":45.17166}},{"facility":"SBIH Kaluga Region Clinical Oncology Dispensary","city":"Kaluga","zip":"248007","country":"Russia","geoPoint":{"lat":54.53063,"lon":36.27}},{"facility":"Murmansk Regional Clinical Hospital named after P.A. Bayandin","city":"Murmansk","zip":"183047","country":"Russia","geoPoint":{"lat":68.96778,"lon":33.09922}},{"facility":"Multidisciplinary clinic Reaviz","city":"Samara","zip":"443011","country":"Russia","geoPoint":{"lat":53.20767,"lon":50.13553}},{"facility":"Groote Schuur Hospital ( Uni of Capetown )","city":"Cape Town","zip":"7506","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"Wilgers Oncology Centre","city":"Pretoria","zip":"0001","country":"South Africa","geoPoint":{"lat":-25.74486,"lon":28.18783}},{"facility":"Sandton Oncology Medical Group","city":"Sandton","zip":"2196","country":"South Africa","geoPoint":{"lat":-26.104,"lon":28.054}},{"facility":"Asan Medical Center","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Centre","city":"Seoul","zip":"135-170","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Hospital Universitari Vall d'Hebron","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario La Paz","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Vajira Hospital","city":"Bangkok","zip":"10300","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Chulalongkorn Hospital","city":"Bangkok","zip":"10330","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Rajavithi Hospital","city":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Faculty of Med. Siriraj Hosp.","city":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Prapokklao Hospital","city":"Chanthaburi","zip":"22000","country":"Thailand","geoPoint":{"lat":12.60961,"lon":102.10447}},{"facility":"Maharaj Nakorn Chiang Mai Hospital","city":"Chiang Mai","zip":"50200","country":"Thailand","geoPoint":{"lat":18.79038,"lon":98.98468}},{"facility":"Prince of Songkla University","city":"Hat Yai","zip":"90110","country":"Thailand","geoPoint":{"lat":7.00836,"lon":100.47668}},{"facility":"Udonthani Cancer Hospital, Udonthani","city":"Muang,Udonthani","zip":"41330","country":"Thailand","geoPoint":{"lat":17.41567,"lon":102.78589}},{"facility":"Medipol University Medical Faculty","city":"Istanbul","zip":"34214","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Ege Uni Medical Faculty Hospital","city":"Izmir","zip":"35100","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"facility":"Municipal Institution City Clinical Hospital #4 of Dnipro City Council","city":"Dnipropetrovsk","state":"Katerynoslav Governorate","zip":"49102","country":"Ukraine","geoPoint":{"lat":48.46664,"lon":35.04066}},{"facility":"Communal Non profit Enterprise Regional Center of Oncology","city":"Kharkiv","state":"Kharkiv Governorate","zip":"61070","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"facility":"Ivano-Frankivsk Regional Oncology Center","city":"Ivano-Frankivsk","zip":"76018","country":"Ukraine","geoPoint":{"lat":48.92312,"lon":24.71248}},{"facility":"RCI Sumy Regional Clinical Oncological Dispensary","city":"Sumy","zip":"40005","country":"Ukraine","geoPoint":{"lat":50.91741,"lon":34.79906}},{"facility":"Birmingham Heartlands Hospital","city":"Birmingham","zip":"B9 5SS","country":"United Kingdom","geoPoint":{"lat":52.48142,"lon":-1.89983}}]},"referencesModule":{"references":[{"pmid":"37268157","type":"DERIVED","citation":"Burotto M, Zvirbule Z, Mochalova A, Runglodvatana Y, Herraez-Baranda L, Liu SN, Chan P, Shearer-Kang E, Liu X, Tosti N, Zanghi JA, Leutgeb B, Felip E. IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications. Ann Oncol. 2023 Aug;34(8):693-702. doi: 10.1016/j.annonc.2023.05.009. Epub 2023 Jun 1."},{"pmid":"33788415","type":"DERIVED","citation":"Felip E, Burotto M, Zvirbule Z, Herraez-Baranda LA, Chanu P, Kshirsagar S, Maiya V, Chan P, Pozzi E, Marchand M, Monchalin M, Tanaka K, Tosti N, Wang B, Restuccia E. Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Clin Pharmacol Drug Dev. 2021 Oct;10(10):1142-1155. doi: 10.1002/cpdd.936. Epub 2021 Mar 31."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Study consisted of 2 parts: Part 1 (Dose Finding) \\& Part 2 (Dose Confirmation). Health care professionals (HCPs) who administered the study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \\& atezolizumab IV, the HCPs were asked to complete two questionnaires: 'HCP SC Versus IV Perspective' \\& 'HCP SC Perspective'.\n\nNo data other than the HCP's responses to these Questionnaires were collected in this study.","recruitmentDetails":"A total of 438 participants with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) who were cancer immunotherapy (CIT)-naïve and for whom prior platinum-based therapy failed took part in the study across 23 countries from 27 December 2018 to 22 November 2024. The study is considered \"Completed\" because all the pre-planned study activities and analyses have been performed.","groups":[{"id":"FG000","title":"Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 milligrams (mg), co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, every 3 weeks (Q3W) on Day 1 of subsequent cycles (1 cycle=21 days) until disease progression (PD), loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"FG001","title":"Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg","description":"Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"FG002","title":"Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"FG003","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"FG004","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"39"},{"groupId":"FG003","numSubjects":"124"},{"groupId":"FG004","numSubjects":"247"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"13"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"26"},{"groupId":"FG003","numSubjects":"124"},{"groupId":"FG004","numSubjects":"247"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"19"},{"groupId":"FG003","numSubjects":"97"},{"groupId":"FG004","numSubjects":"205"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"3"}]},{"type":"New Therapy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Study Ended by Sponsor","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"17"},{"groupId":"FG004","numSubjects":"28"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"11"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Part 1: Intent-to-treat (ITT) population included all enrolled participants. Part 2: Full analysis set (FAS) included all participants who were randomized with participants grouped per their assigned treatment.\n\nHCPs who administered the study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \\& IV, the HCPs were asked to complete 2 questionnaires. No baseline data were collected for the HCPs in this study.","groups":[{"id":"BG000","title":"Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"BG001","title":"Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg","description":"Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"BG002","title":"Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"BG003","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"BG004","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"BG005","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"39"},{"groupId":"BG003","value":"124"},{"groupId":"BG004","value":"247"},{"groupId":"BG005","value":"438"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"58"},{"groupId":"BG004","value":"137"},{"groupId":"BG005","value":"229"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"66"},{"groupId":"BG004","value":"110"},{"groupId":"BG005","value":"209"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"42"},{"groupId":"BG004","value":"72"},{"groupId":"BG005","value":"140"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"27"},{"groupId":"BG003","value":"82"},{"groupId":"BG004","value":"175"},{"groupId":"BG005","value":"298"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"24"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"33"},{"groupId":"BG004","value":"47"},{"groupId":"BG005","value":"85"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"3"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"3"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"36"},{"groupId":"BG003","value":"74"},{"groupId":"BG004","value":"174"},{"groupId":"BG005","value":"303"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"11"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"9"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"36"},{"groupId":"BG004","value":"61"},{"groupId":"BG005","value":"115"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"88"},{"groupId":"BG004","value":"185"},{"groupId":"BG005","value":"314"}]},{"title":"Not Stated","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"8"}]},{"title":"Unknown","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1","populationDescription":"Pharmacokinetic (PK)-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"micrograms per milliliter (μg/mL)","timeFrame":"Pre-dose on Day 1 of Cycle 2 (Cycle length=21 days for cohorts 1 and 3 and 14 days for cohort 2)","groups":[{"id":"OG000","title":"Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"OG001","title":"Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg","description":"Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"OG002","title":"Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"35"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":"42.8"},{"groupId":"OG001","value":"77.5","spread":"51.4"},{"groupId":"OG002","value":"78.3","spread":"88.6"}]}]}]},{"type":"PRIMARY","title":"Part 2: Observed Serum Ctrough of Atezolizumab at Cycle 1","populationDescription":"Per Protocol PK evaluable population included all participants randomized to the atezolizumab SC and atezolizumab IV treatment arms who did not have protocol deviations that could affect Cycle 1 observed Ctrough results.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose on Day 1 of Cycle 2 (Cycle length =21 days)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"205"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":"34.1"},{"groupId":"OG001","value":"89.4","spread":"127.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The null hypothesis that atezolizumab SC is inferior to atezolizumab IV is rejected if the lower bound of the 2-sided 90% confidence interval \\[CI\\] of the geometric mean ratio is greater than or equal to (≥) the non-inferiority margin 0.8.","paramType":"Geometric mean ratio","paramValue":"1.05","ciPctValue":"90.0","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.88","ciUpperLimit":"1.24"}]},{"type":"PRIMARY","title":"Part 2: Area Under the Concentration-Time Curve From Time Zero to 21 Days (AUC 0-21 d) at Cycle 1","populationDescription":"PK-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"micrograms day per mL (μg*day/mL)","timeFrame":"From start of dosing up to Day 21 in Cycle 1 (Cycle length = 21 days)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"246"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3327.9","spread":"19.4"},{"groupId":"OG001","value":"2907.1","spread":"35.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"NON_INFERIORITY","nonInferiorityComment":"The null hypothesis that atezolizumab SC is inferior to atezolizumab IV is rejected if the lower bound of the 2-sided 90% CI of the geometric mean ratio is ≥ the non-inferiority margin 0.8.","paramType":"Geometric mean ratio","paramValue":"0.87","ciPctValue":"90.0","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"0.92"}]},{"type":"SECONDARY","title":"Part 1: Maximum Observed Serum Concentration (Cmax) of Atezolizumab","populationDescription":"PK-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Predose and post dose on Day 1 of Cycle 1 and post dose on Days 3 and 8 of Cycle 1 (Cycle length = 21 days for cohorts 1 and 3 and 14 days for cohort 2)","groups":[{"id":"OG000","title":"Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"OG001","title":"Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg","description":"Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"OG002","title":"Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"251","spread":"40.9"},{"groupId":"OG001","value":"129","spread":"42.5"},{"groupId":"OG002","value":"181","spread":"38.3"}]}]}]},{"type":"SECONDARY","title":"Part 1: Time to Maximum Serum Concentration (Tmax) of Atezolizumab","populationDescription":"PK-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"days","timeFrame":"Predose and post dose on Day 1 of Cycle 1 and post dose on Days 3 and 8 of Cycle 1 (Cycle length = 21 days for cohorts 1 and 3 and 14 days for cohort 2)","groups":[{"id":"OG000","title":"Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"OG001","title":"Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg","description":"Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"OG002","title":"Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","lowerLimit":"2.93","upperLimit":"7.80"},{"groupId":"OG001","value":"3.45","lowerLimit":"3.00","upperLimit":"8.95"},{"groupId":"OG002","value":"3.92","lowerLimit":"2.99","upperLimit":"7.11"}]}]}]},{"type":"SECONDARY","title":"Part 1: Area Under the Concentration-time Curve (AUClast) of Atezolizumab","populationDescription":"PK-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg*day/mL","timeFrame":"Predose and up to 21 days post dose in Cycle 1 for cohorts 1 and 3 and from predose up to 14 days post last dose in Cycle 1 for cohort 2 (Cycle length= 21 days for cohorts 1 and 3 and 14 days for cohort 2)","groups":[{"id":"OG000","title":"Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"OG001","title":"Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg","description":"Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"OG002","title":"Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3870","spread":"38.6"},{"groupId":"OG001","value":"1410","spread":"41.8"},{"groupId":"OG002","value":"2820","spread":"38.6"}]}]}]},{"type":"SECONDARY","title":"Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration","description":"Cycle length =21 days for cohorts 1 and 3 and 14 days for cohort 2. Day=D; Cycle=C.","populationDescription":"PK-evaluable population included all participants who received at least one dose of atezolizumab and had at least 1 evaluable post dose PK sample that could affect PK results. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at a given timepoint.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Cohort 1: Predose: D1 & postdose: D1, 3, 8 of C1; Cohort 2: Pre & postdose: D1 of C1, 3 & postdose: D3, 8 of C1, Predose: D1 of C2; Cohort 3: Pre & postdose: D1 of C1, 2 & postdose: D3, 8 of C1, D2, 4 & 9 of C2 & pre dose: D1 of C3","groups":[{"id":"OG000","title":"Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"OG001","title":"Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg","description":"Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"OG002","title":"Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"39"}]}],"classes":[{"title":"Cycle 1, Day 1: Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"The data was not evaluable as all the samples were below lower limit of quantification (BLLQ)."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"The data was not evaluable as all the samples were BLLQ."},{"groupId":"OG002","value":"NA","spread":"NA","comment":"The data was not evaluable as all the samples were BLLQ."}]}]},{"title":"Cycle 1, Day 1: Post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":"57.8"},{"groupId":"OG001","value":"61.7","spread":"70.9"},{"groupId":"OG002","value":"108","spread":"57.6"}]}]},{"title":"Cycle 1, Day 3: Post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"38"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"247","spread":"40.5"},{"groupId":"OG001","value":"123","spread":"44.3"},{"groupId":"OG002","value":"166","spread":"45.7"}]}]},{"title":"Cycle 1, Day 8: Post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"37"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"230","spread":"36.6"},{"groupId":"OG001","value":"110","spread":"45.0"},{"groupId":"OG002","value":"162","spread":"43.5"}]}]},{"title":"Cycle 2, Day 1: Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"77.5","spread":"51.4"},{"groupId":"OG002","value":"78.3","spread":"88.6"}]}]},{"title":"Cycle 2, Day 1: Post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"87.7","spread":"64.7"}]}]},{"title":"Cycle 2, Day 2: Post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"183","spread":"46.1"}]}]},{"title":"Cycle 2, Day 4: Post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"245","spread":"42.0"}]}]},{"title":"Cycle 2, Day 9: Post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"35"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"225","spread":"37.2"}]}]},{"title":"Cycle 3, Day 1: Pre-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"104","spread":"47.8"},{"groupId":"OG002","value":"123","spread":"57.2"}]}]},{"title":"Cycle 3, Day 1: Post-dose","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"189","spread":"NA","comment":"Since only 1 participant was analysed the geometric coefficient of variation could not be calculated."}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants With Adverse Events (AEs)","description":"An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 5.0 (NCI-CTCAE, v5.0). Percentages have been rounded to one decimal place.","populationDescription":"Safety-evaluable population included all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From initiation of study treatment up to approximately 69 months","groups":[{"id":"OG000","title":"Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"OG001","title":"Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg","description":"Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."},{"id":"OG002","title":"Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"39"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"86.7"},{"groupId":"OG002","value":"84.6"}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants With AEs","description":"An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, V5.0. Percentages have been rounded to one decimal place.","populationDescription":"Safety-evaluable population included all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From initiation of study treatment up to approximately 44.7 months","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"247"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.5"},{"groupId":"OG001","value":"89.9"}]}]}]},{"type":"SECONDARY","title":"Part 2: Model Predicted Ctrough of Atezolizumab at Cycle 1","populationDescription":"PK evaluable population included all participants randomized to the atezolizumab SC and atezolizumab IV treatment arms with at least one post-baseline PK sample. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Cycle 1 (Cycle length=21 days)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"246"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.7","spread":"26.2"},{"groupId":"OG001","value":"97.2","spread":"42.3"}]}]}]},{"type":"SECONDARY","title":"Part 2: Model Predicted Ctrough at Steady State (Ctrough,ss) of Atezolizumab","description":"1 cycle=21 days Abbreviations used-Cycle=C; Day =D; Atezolizumab=atezo.","populationDescription":"PK-evaluable population included all participants who received at least one dose of atezolizumab (atezolizumab SC or atezolizumab IV) and had at least 1 evaluable post dose PK sample. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"μg/mL","timeFrame":"Atezo SC: Pre&postdose C1D1, postdose C1 Days 2,4,8, Pre&postdose C2,D1 and Predose on D1 of C3,4,8,12 and 16 ; Atezo IV: Pre&postdose on C1D1, postdose C1 Days 2,4,8; Pre&postdose C2D1, Predose on D1 of C3,4,8,12, and 16 (up to approximately 16 months)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"246"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":"38.8"},{"groupId":"OG001","value":"205","spread":"58.1"}]}]}]},{"type":"SECONDARY","title":"Part 2: Model Predicted AUC at Steady State (AUCss) of Atezolizumab","description":"1 cycle=21 days Abbreviations used-Cycle=C; Day =D; Atezolizumab=atezo","populationDescription":"PK-evaluable population included all participants who received at least one dose of atezolizumab (atezolizumab SC or atezolizumab IV) and had at least 1 evaluable post dose PK sample. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ug*day/mL","timeFrame":"Atezo SC: Pre&postdose C1D1, postdose C1 Days 2,4,8, Pre&postdose C2,D1 and Predose on D1 of C3,4,8,12 and 16 ; Atezo IV: Pre&postdose on C1D1, postdose C1 Days 2,4,8; Pre&postdose C2D1, Predose on D1 of C3,4,8,12, and 16 (up to approximately 16 months)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"246"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6107","spread":"27.3"},{"groupId":"OG001","value":"6163","spread":"46.7"}]}]}]},{"type":"SECONDARY","title":"Part 2: Objective Response Rate (ORR)","description":"ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST V1.1). CR was defined as the disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \\< 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters (SOD) of all target lesions, taking as reference the baseline SOD in the absence of CR. Percentage of participants who achieved confirmed objective response (CR or PR) have been reported. Percentages have been rounded to one decimal place.","populationDescription":"Response-evaluable population included all participants with measurable disease at baseline.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Up to approximately 25 months","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"245"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","lowerLimit":"5.7","upperLimit":"17.3"},{"groupId":"OG001","value":"11.0","lowerLimit":"7.4","upperLimit":"15.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.8757","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Difference in ORR","paramValue":"0.54","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.56","ciUpperLimit":"7.63"}]},{"type":"SECONDARY","title":"Part 2: Progression-free Survival (PFS)","description":"PFS was defined as the time from study start to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause (whichever occurs first). PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm. PFS was analyzed using the Kaplan-Meier method.","populationDescription":"FAS included all randomized participants, with participants grouped according to their assigned treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to approximately 25 months","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"247"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","lowerLimit":"1.8","upperLimit":"4.2"},{"groupId":"OG001","value":"2.8","lowerLimit":"2.7","upperLimit":"4.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.6906","statisticalMethod":"Log Rank","paramType":"Odds Ratio (OR)","paramValue":"1.05","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"1.33"}]},{"type":"SECONDARY","title":"Part 2: Overall Survival (OS)","description":"OS was defined as the time from the date of study randomization to the date of death from any cause.","populationDescription":"FAS included all randomized participants, with participants grouped according to their assigned treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to approximately 44.7 months","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"247"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"7.5","upperLimit":"12.3"},{"groupId":"OG001","value":"10.9","lowerLimit":"8.5","upperLimit":"14.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9766","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.00","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.78","ciUpperLimit":"1.27"}]},{"type":"SECONDARY","title":"Part 2: Duration of Response (DOR)","description":"DOR was defined as the time from first occurrence of a documented confirmed objective response (CR or PR) to PD as determined by the investigator according to RECIST v1.1. or death from any cause, whichever occurs first. CR was defined as the disappearance of all target lesions and any pathological lymph nodes must have a reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). In addition to the relative increase of 20%, the SODs must also demonstrate an absolute increase of ≥ 5 mm.","populationDescription":"DOR-evaluable population included all participants with a measurable disease at baseline and a post-baseline confirmed objective response (CR or PR).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Up to approximately 25 months","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"27"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","lowerLimit":"4.2","upperLimit":"NA","comment":"The upper limit of the 95% confidence interval (CI) was not estimable due to an insufficient number of participants with events."},{"groupId":"OG001","value":"15.1","lowerLimit":"5.6","upperLimit":"NA","comment":"The upper limit of the 95% CI was not estimable due to an insufficient number of participants with events."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.8375","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.90","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.34","ciUpperLimit":"2.42"}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL) 57 Physical Functioning Score","description":"EORTC IL57 questionnaire has 10 items and covers 3 scales: physical functioning (PF), role functioning (RF) \\& global health status/quality of life (GHS/QoL) \\& 1 item from EORTC IL. PF scale has 5 items evaluating the extent to which participants have trouble doing strenuous activities; taking long walks \\& short walks; need to stay in bed or a chair; need help with eating, dressing, bathing/using toilet. RF scale has 2 items evaluating extent to which participants are limited in doing work \\& pursuing leisure activities in previous week. GHS/QoL scale has 2 items evaluating participants' overall health \\& QoL in previous week. Questions are answered on a 4-point Likert scale (where 1=\"Not at all\" to 4=\"Very much\") for physical and role functioning \\& a 7-point scale (where 1=\"Very poor\" to 7=\"Excellent\") for GHS/QoL. For each scale, mean of the items are linearly transformed to obtain scores from 0-100, where 100 = best possible score. Higher score indicates better outcome.","populationDescription":"FAS included all randomized participants, with participants grouped according to their assigned treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 (Cycle length = 21 days), and Treatment Discontinuation Visit (up to approximately 44 months)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"243"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"243"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.53","spread":"20.37"},{"groupId":"OG001","value":"72.15","spread":"21.94"}]}]},{"title":"Change at Day 1 Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"219"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.23","spread":"19.17"},{"groupId":"OG001","value":"-4.23","spread":"17.01"}]}]},{"title":"Change at Day 1 Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"183"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-4.55","spread":"19.04"},{"groupId":"OG001","value":"-4.99","spread":"17.63"}]}]},{"title":"Change at Day 1 Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"167"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-5.75","spread":"22.04"},{"groupId":"OG001","value":"-4.47","spread":"20.86"}]}]},{"title":"Change at Day 1 Cycle 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.46","spread":"21.40"},{"groupId":"OG001","value":"-2.14","spread":"20.05"}]}]},{"title":"Change at Day 1 Cycle 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.76","spread":"25.68"},{"groupId":"OG001","value":"-0.67","spread":"20.09"}]}]},{"title":"Change at Day 1 Cycle 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"95"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"19.24"},{"groupId":"OG001","value":"-0.42","spread":"19.76"}]}]},{"title":"Change at Day 1 Cycle 10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.46","spread":"22.39"},{"groupId":"OG001","value":"0.82","spread":"20.96"}]}]},{"title":"Change at Day 1 Cycle 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":"22.64"},{"groupId":"OG001","value":"1.14","spread":"20.43"}]}]},{"title":"Change at Day 1 Cycle 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":"19.37"},{"groupId":"OG001","value":"1.11","spread":"18.82"}]}]},{"title":"Change at Day 1 Cycle 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.14","spread":"23.38"},{"groupId":"OG001","value":"2.26","spread":"19.30"}]}]},{"title":"Change at Day 1 Cycle 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.87","spread":"19.10"},{"groupId":"OG001","value":"0.67","spread":"19.30"}]}]},{"title":"Change at Day 1 Cycle 20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.59","spread":"22.30"},{"groupId":"OG001","value":"-0.15","spread":"19.53"}]}]},{"title":"Change at Day 1 Cycle 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.22","spread":"23.54"},{"groupId":"OG001","value":"-1.67","spread":"23.66"}]}]},{"title":"Change at Day 1 Cycle 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"22.69"},{"groupId":"OG001","value":"-1.76","spread":"20.97"}]}]},{"title":"Change at Day 1 Cycle 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":"17.36"},{"groupId":"OG001","value":"-1.94","spread":"23.61"}]}]},{"title":"Change at Day 1 Cycle 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":"14.70"},{"groupId":"OG001","value":"0.51","spread":"19.46"}]}]},{"title":"Change at Day 1 Cycle 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.05","spread":"16.42"},{"groupId":"OG001","value":"0.95","spread":"18.89"}]}]},{"title":"Change at Day 1 Cycle 32","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.67","spread":"21.27"},{"groupId":"OG001","value":"0.61","spread":"22.34"}]}]},{"title":"Change at Day 1 Cycle 34","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.42","spread":"16.40"},{"groupId":"OG001","value":"3.00","spread":"26.62"}]}]},{"title":"Change at Day 1 Cycle 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":"17.24"},{"groupId":"OG001","value":"6.00","spread":"23.59"}]}]},{"title":"Change at Day 1 Cycle 38","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.64","spread":"17.22"},{"groupId":"OG001","value":"4.07","spread":"24.96"}]}]},{"title":"Change at Day 1 Cycle 40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"25.65"},{"groupId":"OG001","value":"1.11","spread":"23.79"}]}]},{"title":"Change at Day 1 Cycle 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.67","spread":"19.76"},{"groupId":"OG001","value":"2.96","spread":"21.36"}]}]},{"title":"Change at Day 1 Cycle 44","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.83","spread":"12.57"},{"groupId":"OG001","value":"5.00","spread":"21.15"}]}]},{"title":"Change at Day 1 Cycle 46","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.83","spread":"16.88"},{"groupId":"OG001","value":"5.88","spread":"26.34"}]}]},{"title":"Change at Day 1 Cycle 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.57","spread":"10.69"},{"groupId":"OG001","value":"8.10","spread":"24.13"}]}]},{"title":"Change at Day 1 Cycle 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.76","spread":"14.76"},{"groupId":"OG001","value":"9.09","spread":"29.25"}]}]},{"title":"Change at Day 1 Cycle 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.22","spread":"12.94"},{"groupId":"OG001","value":"5.33","spread":"24.30"}]}]},{"title":"Change at Day 1 Cycle 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"10.18"},{"groupId":"OG001","value":"6.67","spread":"29.81"}]}]},{"title":"Change at Day 1 Cycle 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.00","spread":"4.71"},{"groupId":"OG001","value":"8.89","spread":"13.88"}]}]},{"title":"Change at Day 1 Cycle 58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.67","spread":"NA","comment":"Standard deviation (SD) was not estimable since only 1 participant was evaluated."},{"groupId":"OG001","value":"3.33","spread":"14.14"}]}]},{"title":"Change at Day 1 Cycle 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.00","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."},{"groupId":"OG001","value":"13.33","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."}]}]},{"title":"Change at Day 1 Cycle 62","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.33","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."},{"groupId":"OG001","value":"13.33","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."}]}]},{"title":"Change at Day 1 Cycle 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"13.33","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."}]}]},{"title":"Change at Treatment Discontinuation Visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"149"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-19.01","spread":"28.26"},{"groupId":"OG001","value":"-15.68","spread":"25.67"}]}]}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in EORTC IL57 Role Functioning Score","description":"EORTC IL57 questionnaire has 10 items and covers 3 scales: PF, RF \\& GHS/QoL \\& 1 item from EORTC IL. PF scale has 5 items evaluating the extent to which participants have trouble doing strenuous activities; taking long walks \\& short walks; need to stay in bed or a chair; need help with eating, dressing, bathing/using toilet. RF scale has 2 items evaluating extent to which participants are limited in doing work \\& pursuing leisure activities in previous week. GHS/QoL scale has 2 items evaluating participants' overall health \\& QoL in previous week. Questions are answered on a 4-point Likert scale (where 1=\"Not at all\" to 4=\"Very much\") for physical and role functioning \\& a 7-point scale (where 1=\"Very poor\" to 7=\"Excellent\") for GHS/QoL. For each scale, mean of the items are linearly transformed to obtain scores from 0-100, where 100 = best possible score. Higher score indicates better outcome.","populationDescription":"FAS included all randomized participants, with participants grouped according to their assigned treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 (Cycle length = 21 days), and Treatment Discontinuation Visit (up to approximately 44 months)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"242"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"242"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74.93","spread":"25.67"},{"groupId":"OG001","value":"74.86","spread":"27.51"}]}]},{"title":"Change at Day 1 Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"218"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"29.46"},{"groupId":"OG001","value":"-4.36","spread":"24.48"}]}]},{"title":"Change at Day 1 Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.29","spread":"27.51"},{"groupId":"OG001","value":"-4.67","spread":"25.83"}]}]},{"title":"Change at Day 1 Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"167"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"26.90"},{"groupId":"OG001","value":"-6.59","spread":"28.63"}]}]},{"title":"Change at Day 1 Cycle 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.34","spread":"31.13"},{"groupId":"OG001","value":"-5.22","spread":"30.27"}]}]},{"title":"Change at Day 1 Cycle 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"119"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"32.14"},{"groupId":"OG001","value":"-5.74","spread":"29.39"}]}]},{"title":"Change at Day 1 Cycle 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"94"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.96","spread":"29.47"},{"groupId":"OG001","value":"-1.95","spread":"25.50"}]}]},{"title":"Change at Day 1 Cycle 10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.63","spread":"29.06"},{"groupId":"OG001","value":"-0.82","spread":"24.71"}]}]},{"title":"Change at Day 1 Cycle 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.29","spread":"29.80"},{"groupId":"OG001","value":"-2.66","spread":"30.20"}]}]},{"title":"Change at Day 1 Cycle 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.11","spread":"22.09"},{"groupId":"OG001","value":"-3.61","spread":"30.24"}]}]},{"title":"Change at Day 1 Cycle 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"29.91"},{"groupId":"OG001","value":"-1.26","spread":"27.12"}]}]},{"title":"Change at Day 1 Cycle 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":"21.60"},{"groupId":"OG001","value":"-2.00","spread":"27.90"}]}]},{"title":"Change at Day 1 Cycle 20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.94","spread":"30.10"},{"groupId":"OG001","value":"-2.65","spread":"27.83"}]}]},{"title":"Change at Day 1 Cycle 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.48","spread":"28.66"},{"groupId":"OG001","value":"-5.09","spread":"34.23"}]}]},{"title":"Change at Day 1 Cycle 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.13","spread":"24.51"},{"groupId":"OG001","value":"-4.41","spread":"29.39"}]}]},{"title":"Change at Day 1 Cycle 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":"36.77"},{"groupId":"OG001","value":"0.54","spread":"27.38"}]}]},{"title":"Change at Day 1 Cycle 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.14","spread":"16.94"},{"groupId":"OG001","value":"5.07","spread":"29.91"}]}]},{"title":"Change at Day 1 Cycle 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.56","spread":"20.24"},{"groupId":"OG001","value":"3.17","spread":"31.01"}]}]},{"title":"Change at Day 1 Cycle 32","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.94","spread":"19.41"},{"groupId":"OG001","value":"-0.76","spread":"31.49"}]}]},{"title":"Change at Day 1 Cycle 34","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.06","spread":"22.70"},{"groupId":"OG001","value":"0.00","spread":"34.20"}]}]},{"title":"Change at Day 1 Cycle 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.03","spread":"17.98"},{"groupId":"OG001","value":"1.67","spread":"31.48"}]}]},{"title":"Change at Day 1 Cycle 38","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.55","spread":"16.82"},{"groupId":"OG001","value":"5.56","spread":"26.20"}]}]},{"title":"Change at Day 1 Cycle 40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.52","spread":"24.10"},{"groupId":"OG001","value":"1.85","spread":"28.52"}]}]},{"title":"Change at Day 1 Cycle 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6.25","spread":"23.46"},{"groupId":"OG001","value":"3.70","spread":"32.11"}]}]},{"title":"Change at Day 1 Cycle 44","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.08","spread":"16.52"},{"groupId":"OG001","value":"7.29","spread":"31.60"}]}]},{"title":"Change at Day 1 Cycle 46","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"23.57"},{"groupId":"OG001","value":"4.90","spread":"32.68"}]}]},{"title":"Change at Day 1 Cycle 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":"20.25"},{"groupId":"OG001","value":"8.33","spread":"31.86"}]}]},{"title":"Change at Day 1 Cycle 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.38","spread":"20.25"},{"groupId":"OG001","value":"13.64","spread":"36.38"}]}]},{"title":"Change at Day 1 Cycle 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":"28.71"},{"groupId":"OG001","value":"1.67","spread":"24.15"}]}]},{"title":"Change at Day 1 Cycle 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-11.11","spread":"34.69"},{"groupId":"OG001","value":"2.08","spread":"36.12"}]}]},{"title":"Change at Day 1 Cycle 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"23.57"},{"groupId":"OG001","value":"-5.56","spread":"19.25"}]}]},{"title":"Change at Day 1 Cycle 58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-33.33","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."},{"groupId":"OG001","value":"0.00","spread":"23.57"}]}]},{"title":"Change at Day 1 Cycle 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."},{"groupId":"OG001","value":"16.67","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."}]}]},{"title":"Change at Day 1 Cycle 62","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."},{"groupId":"OG001","value":"16.67","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."}]}]},{"title":"Change at Day 1 Cycle 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"16.67","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."}]}]},{"title":"Change at Treatment Discontinuation Visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"149"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-20.27","spread":"33.70"},{"groupId":"OG001","value":"-21.14","spread":"34.80"}]}]}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in EORTC IL57 Global Health Status Score","description":"EORTC IL57 questionnaire has 10 items and covers 3 scales: PF, RF \\& GHS/QoL \\& 1 item from EORTC IL. PF scale has 5 items evaluating the extent to which participants have trouble doing strenuous activities; taking long walks \\& short walks; need to stay in bed or a chair; need help with eating, dressing, bathing/using toilet. RF scale has 2 items evaluating extent to which participants are limited in doing work \\& pursuing leisure activities in previous week. GHS/QoL scale has 2 items evaluating participants' overall health \\& QoL in previous week. Questions are answered on a 4-point Likert scale (where 1=\"Not at all\" to 4=\"Very much\") for physical and role functioning \\& a 7-point scale (where 1=\"Very poor\" to 7=\"Excellent\") for GHS/QoL. For each scale, mean of the items are linearly transformed to obtain scores from 0-100, where 100 = best possible score. Higher score indicates better outcome.","populationDescription":"FAS included all randomized participants, with participants grouped according to their assigned treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 (Cycle length = 21 days), and Treatment Discontinuation Visit (up to approximately 44 months)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"242"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"242"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.52","spread":"17.68"},{"groupId":"OG001","value":"63.50","spread":"22.00"}]}]},{"title":"Change at Day 1 Cycle 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"218"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3.54","spread":"21.33"},{"groupId":"OG001","value":"-2.48","spread":"21.77"}]}]},{"title":"Change at Day 1 Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.91","spread":"20.92"},{"groupId":"OG001","value":"-1.83","spread":"23.04"}]}]},{"title":"Change at Day 1 Cycle 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"167"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.71","spread":"19.61"},{"groupId":"OG001","value":"-2.25","spread":"22.21"}]}]},{"title":"Change at Day 1 Cycle 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"134"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"19.26"},{"groupId":"OG001","value":"-1.43","spread":"25.35"}]}]},{"title":"Change at Day 1 Cycle 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"119"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"21.99"},{"groupId":"OG001","value":"0.14","spread":"22.94"}]}]},{"title":"Change at Day 1 Cycle 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"94"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.01","spread":"18.26"},{"groupId":"OG001","value":"1.86","spread":"22.74"}]}]},{"title":"Change at Day 1 Cycle 10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.28","spread":"19.87"},{"groupId":"OG001","value":"0.72","spread":"23.17"}]}]},{"title":"Change at Day 1 Cycle 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"69"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.19","spread":"18.45"},{"groupId":"OG001","value":"-2.78","spread":"18.56"}]}]},{"title":"Change at Day 1 Cycle 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.50","spread":"17.42"},{"groupId":"OG001","value":"1.94","spread":"19.67"}]}]},{"title":"Change at Day 1 Cycle 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.55","spread":"17.77"},{"groupId":"OG001","value":"1.73","spread":"18.52"}]}]},{"title":"Change at Day 1 Cycle 18","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.71","spread":"19.11"},{"groupId":"OG001","value":"0.67","spread":"17.56"}]}]},{"title":"Change at Day 1 Cycle 20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.52","spread":"16.73"},{"groupId":"OG001","value":"-0.95","spread":"18.52"}]}]},{"title":"Change at Day 1 Cycle 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.56","spread":"21.20"},{"groupId":"OG001","value":"0.00","spread":"19.92"}]}]},{"title":"Change at Day 1 Cycle 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.29","spread":"28.20"},{"groupId":"OG001","value":"-2.70","spread":"18.99"}]}]},{"title":"Change at Day 1 Cycle 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.56","spread":"24.95"},{"groupId":"OG001","value":"-2.15","spread":"21.51"}]}]},{"title":"Change at Day 1 Cycle 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.79","spread":"16.72"},{"groupId":"OG001","value":"1.81","spread":"21.17"}]}]},{"title":"Change at Day 1 Cycle 30","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.77","spread":"16.45"},{"groupId":"OG001","value":"3.17","spread":"21.81"}]}]},{"title":"Change at Day 1 Cycle 32","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"18.46"},{"groupId":"OG001","value":"0.38","spread":"17.91"}]}]},{"title":"Change at Day 1 Cycle 34","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"20.07"},{"groupId":"OG001","value":"2.50","spread":"19.70"}]}]},{"title":"Change at Day 1 Cycle 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.52","spread":"15.73"},{"groupId":"OG001","value":"1.67","spread":"20.52"}]}]},{"title":"Change at Day 1 Cycle 38","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.27","spread":"21.11"},{"groupId":"OG001","value":"3.70","spread":"20.66"}]}]},{"title":"Change at Day 1 Cycle 40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.30","spread":"21.50"},{"groupId":"OG001","value":"1.39","spread":"19.85"}]}]},{"title":"Change at Day 1 Cycle 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"17.25"},{"groupId":"OG001","value":"2.31","spread":"20.37"}]}]},{"title":"Change at Day 1 Cycle 44","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.08","spread":"18.23"},{"groupId":"OG001","value":"3.65","spread":"19.95"}]}]},{"title":"Change at Day 1 Cycle 46","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.08","spread":"25.88"},{"groupId":"OG001","value":"2.45","spread":"21.60"}]}]},{"title":"Change at Day 1 Cycle 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.14","spread":"15.54"},{"groupId":"OG001","value":"4.17","spread":"20.35"}]}]},{"title":"Change at Day 1 Cycle 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.38","spread":"17.16"},{"groupId":"OG001","value":"3.03","spread":"21.82"}]}]},{"title":"Change at Day 1 Cycle 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"12.91"},{"groupId":"OG001","value":"-3.33","spread":"16.76"}]}]},{"title":"Change at Day 1 Cycle 54","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.78","spread":"12.73"},{"groupId":"OG001","value":"0.00","spread":"22.27"}]}]},{"title":"Change at Day 1 Cycle 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":"5.89"},{"groupId":"OG001","value":"2.78","spread":"4.81"}]}]},{"title":"Change at Day 1 Cycle 58","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]},{"title":"Change at Day 1 Cycle 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."},{"groupId":"OG001","value":"0.00","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."}]}]},{"title":"Change at Day 1 Cycle 62","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-8.33","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."},{"groupId":"OG001","value":"0.00","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."}]}]},{"title":"Change at Day 1 Cycle 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.00","spread":"NA","comment":"SD was not estimable since only 1 participant was evaluated."}]}]},{"title":"Change at Treatment Discontinuation Visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"149"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-14.53","spread":"26.28"},{"groupId":"OG001","value":"-13.37","spread":"25.42"}]}]}]},{"type":"SECONDARY","title":"Part 2: Overall Satisfaction With Treatment Over Time, Assessed by the Modified Satisfaction With Therapy (SWT) Scale of the Cancer Therapy Satisfaction Questionnaire (CTSQ)","description":"Modified SWT scale of the CTSQ consisted of seven items that measured seven domains related to satisfaction with cancer therapy. These include worthwhile, difficulty, benefits, feelings about side effects, form of therapy, overall satisfaction, and if participants would choose the therapy taking everything into consideration. Each domain is rated on a 5-point scale, with 1 representing the worst response and 5 representing the best response, except in the case of one reverse-scored item. Mean of the items were linearly transformed to obtain scores from 0-100, where 100 was the best possible score. Higher scores indicate higher satisfaction. Here, data for 'overall satisfaction' domain has been presented.","populationDescription":"FAS included all randomized participants, with participants grouped according to their assigned treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"score on a scale","timeFrame":"Day 1 Cycle 3 or Treatment Discontinuation Visit (if treatment discontinued at any visit before Cycle 3) (Cycle length = 21 days)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"191"}]}],"classes":[{"title":"Day 1 Cycle 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"162"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"77.29","spread":"16.08"},{"groupId":"OG001","value":"75.56","spread":"18.61"}]}]},{"title":"Treatment Discontinuation Visit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.67","spread":"19.90"},{"groupId":"OG001","value":"61.21","spread":"19.81"}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants by Their Responses to AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57","description":"The overall patient-reported AE burden was assessed using a single item from the EORTC IL57 questionnaire i.e \"To what extent have you been troubled with side-effects from your treatment?\" The questions were answered on a 4-point Likert scale, where 1=\"Not at all\" to 4=\"Very much\". Higher scores indicated greater AE burden. Percentages have been rounded to one decimal place.","populationDescription":"FAS included all randomized participants, with participants grouped according to their assigned treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, and 64 (Cycle length = 21 days)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"238"}]}],"classes":[{"title":"Baseline - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"238"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49.6"},{"groupId":"OG001","value":"56.7"}]}]},{"title":"Baseline - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"238"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.3"},{"groupId":"OG001","value":"28.6"}]}]},{"title":"Baseline - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"238"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.0"},{"groupId":"OG001","value":"10.1"}]}]},{"title":"Baseline - Very much","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"238"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.2"},{"groupId":"OG001","value":"4.6"}]}]},{"title":"Day 1 Cycle 2 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.2"},{"groupId":"OG001","value":"49.5"}]}]},{"title":"Day 1 Cycle 2 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.8"},{"groupId":"OG001","value":"35.6"}]}]},{"title":"Day 1 Cycle 2 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.3"},{"groupId":"OG001","value":"12.6"}]}]},{"title":"Day 1 Cycle 2 - Very much","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.7"},{"groupId":"OG001","value":"2.3"}]}]},{"title":"Day 1 Cycle 3 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43.2"},{"groupId":"OG001","value":"46.7"}]}]},{"title":"Day 1 Cycle 3 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45.5"},{"groupId":"OG001","value":"41.8"}]}]},{"title":"Day 1 Cycle 3 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.2"},{"groupId":"OG001","value":"8.7"}]}]},{"title":"Day 1 Cycle 3 - Very much","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"184"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1"},{"groupId":"OG001","value":"2.7"}]}]},{"title":"Day 1 Cycle 4 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.8"},{"groupId":"OG001","value":"46.7"}]}]},{"title":"Day 1 Cycle 4 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.6"},{"groupId":"OG001","value":"36.1"}]}]},{"title":"Day 1 Cycle 4 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.6"},{"groupId":"OG001","value":"15.4"}]}]},{"title":"Day 1 Cycle 4 - Very much","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1.8"}]}]},{"title":"Day 1 Cycle 5 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.3"},{"groupId":"OG001","value":"55.9"}]}]},{"title":"Day 1 Cycle 5 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.9"},{"groupId":"OG001","value":"36.0"}]}]},{"title":"Day 1 Cycle 5 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.8"},{"groupId":"OG001","value":"5.9"}]}]},{"title":"Day 1 Cycle 5 - Very much","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2.2"}]}]},{"title":"Day 1 Cycle 6 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.2"},{"groupId":"OG001","value":"49.2"}]}]},{"title":"Day 1 Cycle 6 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.3"},{"groupId":"OG001","value":"40.2"}]}]},{"title":"Day 1 Cycle 6 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.5"},{"groupId":"OG001","value":"8.2"}]}]},{"title":"Day 1 Cycle 6 - Very much","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"122"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2.5"}]}]},{"title":"Day 1 Cycle 8 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"96"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"62.5"},{"groupId":"OG001","value":"58.3"}]}]},{"title":"Day 1 Cycle 8 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"96"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"37.5"}]}]},{"title":"Day 1 Cycle 8 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"96"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.2"},{"groupId":"OG001","value":"4.2"}]}]},{"title":"Day 1 Cycle 10 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.7"},{"groupId":"OG001","value":"54.3"}]}]},{"title":"Day 1 Cycle 10 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.6"},{"groupId":"OG001","value":"44.4"}]}]},{"title":"Day 1 Cycle 10 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.8"},{"groupId":"OG001","value":"1.2"}]}]},{"title":"Day 1 Cycle 12 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.9"},{"groupId":"OG001","value":"50.0"}]}]},{"title":"Day 1 Cycle 12 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.6"},{"groupId":"OG001","value":"45.7"}]}]},{"title":"Day 1 Cycle 12 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"4.3"}]}]},{"title":"Day 1 Cycle 14 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61.3"},{"groupId":"OG001","value":"53.3"}]}]},{"title":"Day 1 Cycle 14 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.8"},{"groupId":"OG001","value":"45.0"}]}]},{"title":"Day 1 Cycle 14 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.9"},{"groupId":"OG001","value":"1.7"}]}]},{"title":"Day 1 Cycle 16 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"60.7"},{"groupId":"OG001","value":"56.6"}]}]},{"title":"Day 1 Cycle 16 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.6"},{"groupId":"OG001","value":"35.8"}]}]},{"title":"Day 1 Cycle 16 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"53"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.7"},{"groupId":"OG001","value":"7.5"}]}]},{"title":"Day 1 Cycle 18 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.6"},{"groupId":"OG001","value":"58.0"}]}]},{"title":"Day 1 Cycle 18 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.4"},{"groupId":"OG001","value":"36.0"}]}]},{"title":"Day 1 Cycle 18 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6.0"}]}]},{"title":"Day 1 Cycle 20 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71.4"},{"groupId":"OG001","value":"59.1"}]}]},{"title":"Day 1 Cycle 20 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.6"},{"groupId":"OG001","value":"31.8"}]}]},{"title":"Day 1 Cycle 20 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"9.1"}]}]},{"title":"Day 1 Cycle 22 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55.6"},{"groupId":"OG001","value":"52.8"}]}]},{"title":"Day 1 Cycle 22 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.9"},{"groupId":"OG001","value":"36.1"}]}]},{"title":"Day 1 Cycle 22 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6"},{"groupId":"OG001","value":"11.1"}]}]},{"title":"Day 1 Cycle 24 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0"},{"groupId":"OG001","value":"55.9"}]}]},{"title":"Day 1 Cycle 24 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.0"},{"groupId":"OG001","value":"38.2"}]}]},{"title":"Day 1 Cycle 24 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.9"}]}]},{"title":"Day 1 Cycle 26 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73.3"},{"groupId":"OG001","value":"51.6"}]}]},{"title":"Day 1 Cycle 26 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.7"},{"groupId":"OG001","value":"41.9"}]}]},{"title":"Day 1 Cycle 26 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6.5"}]}]},{"title":"Day 1 Cycle 28 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.3"},{"groupId":"OG001","value":"56.5"}]}]},{"title":"Day 1 Cycle 28 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.7"},{"groupId":"OG001","value":"39.1"}]}]},{"title":"Day 1 Cycle 28 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4.3"}]}]},{"title":"Day 1 Cycle 30 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.2"},{"groupId":"OG001","value":"70.0"}]}]},{"title":"Day 1 Cycle 30 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.8"},{"groupId":"OG001","value":"25.0"}]}]},{"title":"Day 1 Cycle 30 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.0"}]}]},{"title":"Day 1 Cycle 32 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"59.1"}]}]},{"title":"Day 1 Cycle 32 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.7"},{"groupId":"OG001","value":"36.4"}]}]},{"title":"Day 1 Cycle 32 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.3"},{"groupId":"OG001","value":"4.5"}]}]},{"title":"Day 1 Cycle 34 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.7"},{"groupId":"OG001","value":"65.0"}]}]},{"title":"Day 1 Cycle 34 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.3"},{"groupId":"OG001","value":"35.0"}]}]},{"title":"Day 1 Cycle 36 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"63.6"},{"groupId":"OG001","value":"65.0"}]}]},{"title":"Day 1 Cycle 36 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.4"},{"groupId":"OG001","value":"35.0"}]}]},{"title":"Day 1 Cycle 38 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.7"},{"groupId":"OG001","value":"61.1"}]}]},{"title":"Day 1 Cycle 38 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.3"},{"groupId":"OG001","value":"33.3"}]}]},{"title":"Day 1 Cycle 38 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"}]}]},{"title":"Day 1 Cycle 40 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"72.7"},{"groupId":"OG001","value":"55.6"}]}]},{"title":"Day 1 Cycle 40 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.3"},{"groupId":"OG001","value":"38.9"}]}]},{"title":"Day 1 Cycle 40 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5.6"}]}]},{"title":"Day 1 Cycle 42 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0"},{"groupId":"OG001","value":"66.7"}]}]},{"title":"Day 1 Cycle 42 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.0"},{"groupId":"OG001","value":"33.3"}]}]},{"title":"Day 1 Cycle 44 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0"},{"groupId":"OG001","value":"68.8"}]}]},{"title":"Day 1 Cycle 44 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.0"},{"groupId":"OG001","value":"31.3"}]}]},{"title":"Day 1 Cycle 46 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"87.5"},{"groupId":"OG001","value":"76.5"}]}]},{"title":"Day 1 Cycle 46 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"23.5"}]}]},{"title":"Day 1 Cycle 46 - Quite a bit","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.5"},{"groupId":"OG001","value":"0"}]}]},{"title":"Day 1 Cycle 48 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"71.4"}]}]},{"title":"Day 1 Cycle 48 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"28.6"}]}]},{"title":"Day 1 Cycle 50 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"63.6"}]}]},{"title":"Day 1 Cycle 50 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"36.4"}]}]},{"title":"Day 1 Cycle 52 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"60.0"}]}]},{"title":"Day 1 Cycle 52 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"40.0"}]}]},{"title":"Day 1 Cycle 54 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"50.0"}]}]},{"title":"Day 1 Cycle 54 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"50.0"}]}]},{"title":"Day 1 Cycle 56 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"0"}]}]},{"title":"Day 1 Cycle 56 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"100"}]}]},{"title":"Day 1 Cycle 58 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"50.0"}]}]},{"title":"Day 1 Cycle 58 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"50.0"}]}]},{"title":"Day 1 Cycle 60 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"0"}]}]},{"title":"Day 1 Cycle 60 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"100"}]}]},{"title":"Day 1 Cycle 62 - Not at all","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"0"}]}]},{"title":"Day 1 Cycle 62 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"100"}]}]},{"title":"Day 1 Cycle 64 - A little","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"100"}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants With Ant-Drug Antibodies (ADAs) to Atezolizumab After SC or IV Administration","description":"The percentage of ADA-positive participants after atezolizumab administration was reported. Participants who received atezolizumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following atezolizumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Percentages have been rounded to one decimal place.","populationDescription":"Safety-evaluable population included all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From Cycle 1 Day 1 (Cycle length = 21 days) up to treatment discontinuation visit (Up to approximately 20 months)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."},{"id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"228"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3"},{"groupId":"OG001","value":"20.6"}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants With ADAs to rHuPH20 After SC Administration","description":"The percentage of ADA-positive participants after atezolizumab SC formulated with rHuPH20 administration was reported. Participants who received atezolizumab SC formulated with rHuPH20 were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following rHuPH20 exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 t.u. greater than the titer of the baseline sample (treatment-enhanced ADA response). Percentages have been rounded to one decimal place.","populationDescription":"Safety-evaluable population included all participants who received at least one dose of atezolizumab SC formulated with rHuPH20. Overall number analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"From Cycle 1 Day 1 (Cycle length = 21 days) up to treatment discontinuation visit (Up to approximately 20 months)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"228"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7"}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Health Care Professionals (HCPs) by Their Response to Question 2 of HCP SC Versus IV Perspective Questionnaire","description":"The HCP SC versus IV Perspective Questionnaire consisted of five items evaluating the number of atezolizumab SC and IV administrations done, convenience, potential time savings, and overall satisfaction with atezolizumab SC and atezolizumab IV, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as an IV infusion and as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 2 is being reported here: Question 2: Which formulation of atezolizumab (SC or IV) do you think is more convenient for you? Responses to this question are reported in the data table. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'first participant in \\[FPI\\]' date to 'last participant last visit \\[LPLV\\]' for Part 2).","populationDescription":"Overall number analyzed included HCPs who completed Question 2 of the questionnaire.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of HCPs","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 48 months)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV/Atezolizumab SC","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, or atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity. HCPs who administered the IV or SC formulations completed the HCP SC versus IV Perspective Questionnaire."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"}]}],"classes":[{"title":"Atezolizumab SC is much more convenient","categories":[{"measurements":[{"groupId":"OG000","value":"24.0"}]}]},{"title":"Atezolizumab SC is a little more convenient","categories":[{"measurements":[{"groupId":"OG000","value":"16.0"}]}]},{"title":"Both formulations are equally convenient","categories":[{"measurements":[{"groupId":"OG000","value":"26.0"}]}]},{"title":"Atezolizumab IV is a little more convenient","categories":[{"measurements":[{"groupId":"OG000","value":"12.0"}]}]},{"title":"Atezolizumab IV is much more convenient","categories":[{"measurements":[{"groupId":"OG000","value":"22.0"}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Versus IV Perspective Questionnaire","description":"The HCP SC versus IV Perspective Questionnaire consisted of five items evaluating the number of atezolizumab SC and IV administrations done, convenience, potential time savings, and overall satisfaction with atezolizumab SC and atezolizumab IV, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as an IV infusion and as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 3 is being reported here: Question 3: If used in routine practice, do you think administering atezolizumab SC could save staff time compared to atezolizumab IV? The responses to this question could be Yes; No; Unsure. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2).","populationDescription":"Overall number analyzed included HCPs who completed Question 3 of the questionnaire.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of HCPs","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 48 months)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV/Atezolizumab SC","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, or atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity. HCPs who administered the IV or SC formulations completed the HCP SC versus IV Perspective Questionnaire."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"74.0"}]}]},{"title":"Unsure","categories":[{"measurements":[{"groupId":"OG000","value":"14.0"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"12.0"}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Versus IV Perspective Questionnaire","description":"The HCP SC versus IV Perspective Questionnaire consisted of five items evaluating the number of atezolizumab SC and IV administrations done, convenience, potential time savings, and overall satisfaction with atezolizumab SC and atezolizumab IV, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as an IV infusion and as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 4 is being reported here: Question 4: Overall, were you more satisfied with atezolizumab SC or atezolizumab IV? The responses included: More satisfied with atezolizumab SC; Equally satisfied with both formulations; More satisfied with atezolizumab IV. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2).","populationDescription":"Overall number analyzed included HCPs who completed Question 4 of the questionnaire.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of HCPs","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC and IV across all participants in Part 2 (Up to approximately 48 months)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab IV/Atezolizumab SC","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, or atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity. HCPs who administered the IV or SC formulations completed the HCP SC versus IV Perspective Questionnaire."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"50"}]}],"classes":[{"title":"More satisfied with atezolizumab SC","categories":[{"measurements":[{"groupId":"OG000","value":"32.0"}]}]},{"title":"Equally satisfied with both formulations","categories":[{"measurements":[{"groupId":"OG000","value":"38.0"}]}]},{"title":"More satisfied with atezolizumab IV","categories":[{"measurements":[{"groupId":"OG000","value":"30.0"}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of HCPs by Their Response to Question 2 of the HCP SC Perspective Questionnaire","description":"The HCP SC Perspective Questionnaire consisted of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 2 is being reported here: Question 2: Do you think atezolizumab SC is convenient? The responses to this question could be: Yes; No; and Unsure. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2). Percentages have been rounded to one decimal place.","populationDescription":"Overall number analyzed included HCPs who completed Question 2 of the questionnaire.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of HCPs","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity. HCPs who administered the SC formulation completed the HCP SC Perspective Questionnaire."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"78.6"}]}]},{"title":"Unsure","categories":[{"measurements":[{"groupId":"OG000","value":"14.3"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"7.1"}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Perspective Questionnaire","description":"The HCP SC Perspective Questionnaire consisted of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 3 is being reported here: Question 3: Overall, how easy did you find atezolizumab SC administration? The responses to this question could be: Very easy; Fairly easy; Not at all easy. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2). Percentages have been rounded to one decimal place.","populationDescription":"Overall number analyzed included HCPs who completed Question 3 of the questionnaire.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of HCPs","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity. HCPs who administered the SC formulation completed the HCP SC Perspective Questionnaire."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"}]}],"classes":[{"title":"Very easy","categories":[{"measurements":[{"groupId":"OG000","value":"54.8"}]}]},{"title":"Fairly easy","categories":[{"measurements":[{"groupId":"OG000","value":"34.5"}]}]},{"title":"Not at all easy","categories":[{"measurements":[{"groupId":"OG000","value":"10.7"}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of HCPs by Their Response to Question 4 of the HCP SC Perspective Questionnaire","description":"The HCP SC Perspective Questionnaire consisted of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 4 is being reported here: Question 4: Overall, how satisfied were you with atezolizumab SC? The responses to this question could be: Very satisfied; Satisfied; Dissatisfied; Very dissatisfied. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2). Percentages have been rounded to one decimal place.","populationDescription":"Overall number analyzed included HCPs who completed Question 4 of the questionnaire.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of HCPs","timeFrame":"After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months)","groups":[{"id":"OG000","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity. HCPs who administered the SC formulation completed the HCP SC Perspective Questionnaire."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"84"}]}],"classes":[{"title":"Very satisfied","categories":[{"measurements":[{"groupId":"OG000","value":"34.5"}]}]},{"title":"Satisfied","categories":[{"measurements":[{"groupId":"OG000","value":"50.0"}]}]},{"title":"Dissatisfied","categories":[{"measurements":[{"groupId":"OG000","value":"13.1"}]}]},{"title":"Very dissatisfied","categories":[{"measurements":[{"groupId":"OG000","value":"2.4"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From initiation of the study treatment up to approximately 69 months in Part 1 and up to approximately 44.7 months in Part 2","description":"Safety-evaluable population=all participants who received at least one dose of atezolizumab (IV or SC), with participants grouped according to treatment received.\n\nHCPs who administered study treatment to participants were not enrolled in the study. To evaluate the HCPs' reported experience with administration of atezolizumab SC \\& IV, they were asked to complete 2 questionnaires: HCP SC Versus IV Perspective \\& HCP SC Perspective. No adverse event data were collected for the HCPs in this study.","eventGroups":[{"id":"EG000","title":"Part 1 Cohort 1: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection on Cycle 1 Day 1 (1 cycle=21 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.","deathsNumAffected":4,"deathsNumAtRisk":13,"seriousNumAffected":2,"seriousNumAtRisk":13,"otherNumAffected":13,"otherNumAtRisk":13},{"id":"EG001","title":"Part 1 Cohort 2: Atezolizumab SC Co-mix 1200 mg","description":"Participants received atezolizumab, 1200 mg, co-mixed with rHuPH20, as SC injection, Q2W, on Day 1 of the first 3 cycles (Cycle 1-3=14 days), followed by atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.","deathsNumAffected":6,"deathsNumAtRisk":15,"seriousNumAffected":4,"seriousNumAtRisk":15,"otherNumAffected":12,"otherNumAtRisk":15},{"id":"EG002","title":"Part 1 Cohort 3: Atezolizumab SC Co-mix 1800 mg","description":"Participants received atezolizumab, 1800 mg, co-mixed with rHuPH20, as SC injection, Q3W, on Day 1 of first 3 cycles, followed by atezolizumab, 1200 mg, as an IV infusion, Q3W on Day 1 for subsequent cycles (1 cycle=21 days) until PD, loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.","deathsNumAffected":19,"deathsNumAtRisk":39,"seriousNumAffected":8,"seriousNumAtRisk":39,"otherNumAffected":31,"otherNumAtRisk":39},{"id":"EG003","title":"Part 2: Atezolizumab IV 1200 mg","description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","deathsNumAffected":97,"deathsNumAtRisk":124,"seriousNumAffected":35,"seriousNumAtRisk":124,"otherNumAffected":91,"otherNumAtRisk":124},{"id":"EG004","title":"Part 2: Atezolizumab SC 1875 mg","description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","deathsNumAffected":206,"deathsNumAtRisk":247,"seriousNumAffected":50,"seriousNumAtRisk":247,"otherNumAffected":204,"otherNumAtRisk":247}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Splenic infarction","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Autoimmune myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":247}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":247}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Oesophageal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Oesophageal stenosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":247}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":247}]},{"term":"Enteritis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Pneumocystis jirovecii pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":7,"numAffected":6,"numAtRisk":124},{"groupId":"EG004","numEvents":8,"numAffected":8,"numAtRisk":247}]},{"term":"Pneumonia aspiration","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":247}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Tracheobronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":247}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Vascular device infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Blood sodium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":247}]},{"term":"Balance disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":247}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Nephropathy","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Tubulointerstitial nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":247}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":124},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":247}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":247}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":247}]},{"term":"Drug reaction with eosinophilia and systemic symptoms","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Toxic epidermal necrolysis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":15},{"groupId":"EG002","numEvents":16,"numAffected":13,"numAtRisk":39},{"groupId":"EG003","numEvents":30,"numAffected":21,"numAtRisk":124},{"groupId":"EG004","numEvents":54,"numAffected":47,"numAtRisk":247}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":124},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":247}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":124},{"groupId":"EG004","numEvents":9,"numAffected":8,"numAtRisk":247}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":124},{"groupId":"EG004","numEvents":18,"numAffected":9,"numAtRisk":247}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":247}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":124},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":247}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":9,"numAffected":7,"numAtRisk":124},{"groupId":"EG004","numEvents":25,"numAffected":21,"numAtRisk":247}]},{"term":"Periorbital oedema","organSystem":"Eye disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":12,"numAffected":12,"numAtRisk":247}]},{"term":"Anal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":9,"numAffected":9,"numAtRisk":124},{"groupId":"EG004","numEvents":17,"numAffected":17,"numAtRisk":247}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":39},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":124},{"groupId":"EG004","numEvents":27,"numAffected":21,"numAtRisk":247}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":7,"numAffected":4,"numAtRisk":247}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":124},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":247}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":124},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":247}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":247}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":15},{"groupId":"EG002","numEvents":12,"numAffected":9,"numAtRisk":39},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":124},{"groupId":"EG004","numEvents":16,"numAffected":15,"numAtRisk":247}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":39},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":124},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":247}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":15},{"groupId":"EG002","numEvents":12,"numAffected":7,"numAtRisk":39},{"groupId":"EG003","numEvents":11,"numAffected":9,"numAtRisk":124},{"groupId":"EG004","numEvents":19,"numAffected":19,"numAtRisk":247}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":39},{"groupId":"EG003","numEvents":9,"numAffected":9,"numAtRisk":124},{"groupId":"EG004","numEvents":14,"numAffected":11,"numAtRisk":247}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":15},{"groupId":"EG002","numEvents":14,"numAffected":11,"numAtRisk":39},{"groupId":"EG003","numEvents":20,"numAffected":16,"numAtRisk":124},{"groupId":"EG004","numEvents":33,"numAffected":31,"numAtRisk":247}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":247}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Injection site inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":15,"numAffected":5,"numAtRisk":247}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":247}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":39},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":124},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":247}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":8,"numAffected":6,"numAtRisk":124},{"groupId":"EG004","numEvents":16,"numAffected":12,"numAtRisk":247}]},{"term":"Xerosis","organSystem":"General disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":247}]},{"term":"Asymptomatic bacteriuria","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":247}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":11,"numAffected":10,"numAtRisk":124},{"groupId":"EG004","numEvents":19,"numAffected":19,"numAtRisk":247}]},{"term":"Conjunctivitis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Folliculitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Furuncle","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":4,"numAffected":2,"numAtRisk":247}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":247}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":124},{"groupId":"EG004","numEvents":15,"numAffected":13,"numAtRisk":247}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":124},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":247}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":39},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":124},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":247}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":11,"numAffected":8,"numAtRisk":124},{"groupId":"EG004","numEvents":15,"numAffected":11,"numAtRisk":247}]},{"term":"Vestibular neuronitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Injection related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":9,"numAffected":5,"numAtRisk":247}]},{"term":"Lack of injection site rotation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":39},{"groupId":"EG003","numEvents":12,"numAffected":10,"numAtRisk":124},{"groupId":"EG004","numEvents":25,"numAffected":24,"numAtRisk":247}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":39},{"groupId":"EG003","numEvents":14,"numAffected":13,"numAtRisk":124},{"groupId":"EG004","numEvents":28,"numAffected":23,"numAtRisk":247}]},{"term":"Blood albumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":247}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":39},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":124},{"groupId":"EG004","numEvents":21,"numAffected":20,"numAtRisk":247}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":39},{"groupId":"EG003","numEvents":9,"numAffected":2,"numAtRisk":124},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":247}]},{"term":"Blood cholesterol increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":15},{"groupId":"EG002","numEvents":8,"numAffected":5,"numAtRisk":39},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":247}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":39},{"groupId":"EG003","numEvents":8,"numAffected":7,"numAtRisk":124},{"groupId":"EG004","numEvents":8,"numAffected":6,"numAtRisk":247}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":124},{"groupId":"EG004","numEvents":16,"numAffected":12,"numAtRisk":247}]},{"term":"Blood magnesium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":247}]},{"term":"Blood sodium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":124},{"groupId":"EG004","numEvents":15,"numAffected":7,"numAtRisk":247}]},{"term":"Blood triglycerides increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":124},{"groupId":"EG004","numEvents":7,"numAffected":7,"numAtRisk":247}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Neutrophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":39},{"groupId":"EG003","numEvents":4,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG003","numEvents":7,"numAffected":6,"numAtRisk":124},{"groupId":"EG004","numEvents":18,"numAffected":15,"numAtRisk":247}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":15},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":39},{"groupId":"EG003","numEvents":16,"numAffected":15,"numAtRisk":124},{"groupId":"EG004","numEvents":32,"numAffected":31,"numAtRisk":247}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":247}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":9,"numAffected":6,"numAtRisk":124},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":247}]},{"term":"Hypercreatininaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":10,"numAffected":7,"numAtRisk":124},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":247}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":39},{"groupId":"EG003","numEvents":22,"numAffected":13,"numAtRisk":124},{"groupId":"EG004","numEvents":18,"numAffected":12,"numAtRisk":247}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":39},{"groupId":"EG003","numEvents":15,"numAffected":11,"numAtRisk":124},{"groupId":"EG004","numEvents":14,"numAffected":9,"numAtRisk":247}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":124},{"groupId":"EG004","numEvents":15,"numAffected":14,"numAtRisk":247}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":9,"numAffected":6,"numAtRisk":124},{"groupId":"EG004","numEvents":9,"numAffected":8,"numAtRisk":247}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":39},{"groupId":"EG003","numEvents":9,"numAffected":8,"numAtRisk":124},{"groupId":"EG004","numEvents":9,"numAffected":8,"numAtRisk":247}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":39},{"groupId":"EG003","numEvents":17,"numAffected":13,"numAtRisk":124},{"groupId":"EG004","numEvents":18,"numAffected":17,"numAtRisk":247}]},{"term":"Vitamin B12 deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Vitamin D deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":10,"numAffected":7,"numAtRisk":39},{"groupId":"EG003","numEvents":8,"numAffected":7,"numAtRisk":124},{"groupId":"EG004","numEvents":21,"numAffected":18,"numAtRisk":247}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":39},{"groupId":"EG003","numEvents":9,"numAffected":9,"numAtRisk":124},{"groupId":"EG004","numEvents":21,"numAffected":21,"numAtRisk":247}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":247}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":247}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":39},{"groupId":"EG003","numEvents":6,"numAffected":4,"numAtRisk":124},{"groupId":"EG004","numEvents":13,"numAffected":11,"numAtRisk":247}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":7,"numAffected":6,"numAtRisk":124},{"groupId":"EG004","numEvents":17,"numAffected":13,"numAtRisk":247}]},{"term":"Hair follicle tumour benign","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Melanocytic naevus","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":39},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":124},{"groupId":"EG004","numEvents":6,"numAffected":5,"numAtRisk":247}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":124},{"groupId":"EG004","numEvents":21,"numAffected":17,"numAtRisk":247}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":124},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":247}]},{"term":"Sensory loss","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Trigeminal neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":124},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":247}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":8,"numAffected":8,"numAtRisk":124},{"groupId":"EG004","numEvents":8,"numAffected":8,"numAtRisk":247}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":247}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":15},{"groupId":"EG002","numEvents":10,"numAffected":7,"numAtRisk":39},{"groupId":"EG003","numEvents":9,"numAffected":9,"numAtRisk":124},{"groupId":"EG004","numEvents":37,"numAffected":33,"numAtRisk":247}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":247}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":39},{"groupId":"EG003","numEvents":21,"numAffected":20,"numAtRisk":124},{"groupId":"EG004","numEvents":27,"numAffected":26,"numAtRisk":247}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":39},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":124},{"groupId":"EG004","numEvents":9,"numAffected":7,"numAtRisk":247}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":124},{"groupId":"EG004","numEvents":6,"numAffected":5,"numAtRisk":247}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":247}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":247}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":7,"numAffected":4,"numAtRisk":39},{"groupId":"EG003","numEvents":13,"numAffected":12,"numAtRisk":124},{"groupId":"EG004","numEvents":14,"numAffected":14,"numAtRisk":247}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":39},{"groupId":"EG003","numEvents":14,"numAffected":10,"numAtRisk":124},{"groupId":"EG004","numEvents":15,"numAffected":13,"numAtRisk":247}]},{"term":"Rash erythematous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":39},{"groupId":"EG003","numEvents":10,"numAffected":3,"numAtRisk":124},{"groupId":"EG004","numEvents":5,"numAffected":3,"numAtRisk":247}]},{"term":"Venous thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA version 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":39},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":124},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":247}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffman-La-Roche","email":"genentech@druginfo.com","phone":"800 821-8590"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2023-02-07","uploadDate":"2023-04-25T04:45","filename":"Prot_000.pdf","size":3440071},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-06-06","uploadDate":"2023-04-25T04:45","filename":"SAP_001.pdf","size":1898839}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Bulgaria"],"submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-05-19","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000594389","term":"atezolizumab"}]}},"hasResults":true}